eravacycline

Eravacycline is a fully synthetic, halogenated tetracycline-class antibiotic (specifically a fluorocycline) developed for the treatment of complicated intra-abdominal infections (cIAI) in adults. It is structurally related to tigecycline and exhibits broad-spectrum activity against both Gram-positive and Gram-negative bacteria, including many multidrug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA) and carbapenem-resistant Enterobacteriaceae. Eravacycline acts by binding reversibly to the bacterial 30S ribosomal subunit, inhibiting protein synthesis by preventing the incorporation of amino acids into elongating peptide chains. This results in bacteriostatic activity against most organisms but can be bactericidal against certain strains like Escherichia coli and Klebsiella pneumoniae. The drug was first approved by the FDA in August 2018 for intravenous use[2][4][5][6].

Brand names

Xerava

Other names

eravacycline